

International A ation No PCT/EP 03/03060

A. CLASSIFICATION OF SUBJECT MATTER IPC 7 A61K31/44 A61K31/45

A61P35/00

A61P43/00 ·

A61K31/495

A61K31/4406 A61P37/00

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)  $IPC\ 7\ A61K$ 

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

PAJ CHEM ARS Data RINGTS

	ENTS CONSIDERED TO BE RELEVANT	Newart processes	Relevant to claim No.
Category °	Citation of document, with indication, where appropriate, of the re	nevant passages	Tielevan to dam tvo.
X	DE 196 24 659 A (KLINGE CO CHEM 8 January 1998 (1998-01-08) page 64; examples 150,153,158,15 page 36 page 2, line 1-26 page 77, line 51 -page 78, line	9,162	1-11,14
X	DE 197 56 235 A (KLINGE CO CHEM 1 July 1999 (1999-07-01) page 33; examples 82,120 page 74, line 40 -page 75, line		1-11,14
X	DE 196 24 704 A (KLINGE CO CHEM 8 January 1998 (1998-01-08) claim 9 page 78 -page 79, line 7	PHARM FAB) .	1-11,14
X Furt	her documents are listed in the continuation of box C.	Patent family members are listed	in annex.
"A" docume consk "E" earlier filing of the docume which clustion other "P" docume of the country	ent defining the general state of the art which is not detend to be of particular relevance document but published on or after the international date of the state of the publication date of another is cited to establish the publication date of another in or other special reason (as specified) ent referring to an oral disclosure, use, exhibition or means ent published prior to the international filing date but han the priority date claimed	<ul> <li>"T" later document published after the International filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</li> <li>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone</li> <li>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</li> <li>"&amp;" document member of the same patent family</li> </ul>	
Date of the	actual completion of the International search	Date of mailing of the international se	arch report
9	July 2003	21/07/2003	
Name and	mailing address of the ISA  European Patent Office, P.B. 5818 Patentlaan 2  NL - 2280 HV Rijswijk  Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  Fax: (+31-70) 340-3016	Authorized officer  Bonzano, C	



International A station No PCT/EP 03/03060

Category °	ation) DOCUMENTS CONSIDERED TO BE RELEVANT  Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
		1 lolovair to olamitive
A	DE 197 56 212 A (KLINGE CO CHEM PHARM FAB) 1 July 1999 (1999-07-01)	
A	DE 197 56 236 A (KLINGE CO CHEM PHARM FAB) 1 July 1999 (1999-07-01)	
Υ	US 4 778 796 A (UNO HITOSHI ET AL) 18 October 1988 (1988-10-18) column 24; example 85 column 25; example 91 column 1, line 7 - line 37	1-11
X -	DE 197 56 261 A (KLINGE CO CHEM PHARM FAB) 1 July 1999 (1999-07-01) page 2, line 21 - line 50 page 38	1-6,11
<b>Y</b>	NIE DAOTAI ET AL: "Eicosanoid regulation of angiogenesis: Role of endothelial arachidonate 12-lipoxygenase." BLOOD, vol. 95, no. 7, 1 April 2000 (2000-04-01), pages 2304-2311, XP002208812 ISSN: 0006-4971 page 2310, column 1, paragraph 1 page 2310, column 2, paragraph 3 - paragraph 4	1-11
Α	COLAVITTI RENATA ET AL: "Reactive oxygen species as downstream mediators of angiogenic signaling by vascular endothelial growth factor receptor-2/KDR." JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 277, no. 5, February 2002 (2002-02), pages 3101-3108, XP001074657 February, 2002 ISSN: 0021-9258 page 3101, column 2, paragraph 3	
Y	NISHIKAWA ET AL: "Acrylamide derivatives as antiallergic agents. 2. Synthesis and structure activity relationships of N-'4-'4-(diphenylmethyl)-1- piperazinyl!butyl!-3-(3-pyridyl)acrylamide s" JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY. WASHINGTON, US, vol. 32, no. 3, 1989, pages 583-593, XP002101517 ISSN: 0022-2623 page 587; examples 1A,16A page 588; examples 1A,21,1A; table V page 583, column 1, paragraph 1	1-11
•		



International App on No PCT/EP 03/03060

		PLIZEP US	
	ation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category °	Citation of document, with Indication, where appropriate, of the relevant passages		Relevant to claim No.
A .	WO 98 02170 A (LEUVEN RESEARCH AND DEV V Z M ;GEN HOSPITAL CORP (US)) 22 January 1998 (1998-01-22) page 3, paragraph 2		
	·		
	·		

## FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

## Continuation of Box I.2

Claims 1-9,11,12 relate to the treatment of diseases and to diagnostic applications which are actually not well defined. The use of the definitions "inhibition or reduction of angiogenesis, disease responding to inhibition or reduction of angiogenesis, disease responding to inhibition or reduction of VEGF production; in vitro diagnostic method" in the present context is considered to lead to a lack of clarity within the meaning of Article 6 PCT. The lack of clarity is such as to render a meaningful complete search not fully possible.

Moreover, the claims cover all diseases responding to inhibition or reduction of angiogenesis and all in vitro diagnostic methods, whereas the application provides support within the meaning of Article 6 PCT and/or disclosure within the meaning of Article 5 PCT for only a very limited number of such diseases and diagnostic methods. In the present case, the claims so lack support, and the application so lacks disclosure, that a meaningful search over the whole of the claimed scope is impossible.

Present claims 1-14 relate to an extremely large number of possible compounds. Support within the meaning of Article 6 PCT and disclosure within the meaning of Article 5 PCT is to be found, however, for only a very small proportion of the compounds claimed. In the present case, the claims so lack support, and the application so lacks disclosure, that a meaningful search over the whole of the claimed scope is impossible. Consequently, the search has been restricted to the parts relating to the compounds mentioned in the examples, for the treatment of the diseases mentioned claims 10 and to the in vitro diagnostic methods for the diseases mentioned in claim 13, with due regard to the general idea underlying the present invention.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

International application No. PCT/EP 03/03060

## INTERNATIONAL SEARCH REPORT

Box I	Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)
This Inte	mational Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:
1. X	Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:
	Although claim 14 is directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. 🛚 🗓	Claims Nos.:  because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
	see FURTHER INFORMATION sheet PCT/ISA/210
3.	Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).
Box II	Observations where unity of invention is lacking (Continuation of item 2 of first sheet)
This Inte	emational Searching Authority found multiple inventions in this international application, as follows:
1.	As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2.	As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3.	As only some of the required additional search fees were timely paid by the applicant, this international Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4.	No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:
Rema	The additional search tees were accompanied by the applicant's protest.  No protest accompanied the payment of additional search fees.

International Algorithm No
PCT/EP 03/03060

Patent document cited in search report		Publication date		Patent family member(s)	Publication date
DE 19624659	Α	-08-01-1998	DE AT	19624659 A1 224888 T	08-01-1998 15-10-2002 26-07-2001
			AU	736206 B2	07-01-1998
			AU BR	3262597 A 9709823 A	10-08-1999
			CA	2257448 A1	24-12-1997
			CN	1228777 A	15-09-1999
			CZ	9804093 A3	12-05-1999
			DE	69715888 D1	31-10-2002
			DK	923570 T3	20-01-2003
			MO	9748696 A1	24-12-1997
			EP	0923570 A1	23-06-1999 16-01 <b>-</b> 2003
			ES	2179351 T3 9903766 A2	28-09-2000
			HU JP	2000516913 T	19-12-2000
•			KR	2000022333 A	25-04-2000
			PT	923570 T	31-12-2002
			RÜ	2200734 C2	20-03-2003
			TR	9802651 T2	21-04-1999
			ZA	9705437 A	10-02-1998 
DE 19756235	A	01-07-1999	DE	19756235 A1	01-07-1999
			AU	2162599 A	05-07-1999 24-06-1999
			WO	9931060 A2 1044197 A2	18-10-2000
			EP ZA	9811241 A	09-06-1999
DE 19624704		08-01-1998	DE	19624704 A1	08-01-1998
DE 130E4701	••		AT	223912 T	15-09-2002
			AU	3342097 A	07-01-1998
			DE	69715439 D1	17-10-2002
			DE	69715439 T2	22-05-2003 23-12-2002
			DK WO	934309 T3 9748695 A1	24-12-1997
			EP	0934309 A1	11-08-1999
			ËS	2178779 T3	01-01-2003
			ĴΡ	2000512651 T	26-09-2000
			PT	934309 T	31-12-2002
			US	6444823 B1	03-09-2002
			ZA	9705439 A 	23-02-1998 
DE 19756212	Α	01-07-1999	DE	19756212 A1	01-07-1999 05-07-1999
			WO WO	2414699 A 9931087 A1	24-06-1999
			WU EP	1042315 A1	11-10-2000
			JP	2002508367 T	19-03-2002
			ZA	9811231 A	08-06-1999
DE 19756236	A	01-07-1999	DE	19756236 A1	01-07-1999
			ΑU	2054399 A	05-07-1999
			MO	9931063 A1	24-06-1999 20-12-2000
			EP	1060163 A1 2002508356 T	20-12-2000 19-03-2002
•			JP ZA	9811235 A	08-06-1999
us 4778796	A	18-10-1988	AT	62676 T	15-05-1991
50 0, 5			CA	1262726 A1	07-11-1989
			DE	3678763 D1	23-05-1991

International Appropriation No PCT/EP 03/03060

Patent document cited in search report	. Publication date	Patent family member(s)	Publication date ;
. US 4778796 A		EP 0210782 A2 ES 2000534 A6 JP 1608094 C JP 2033705 B JP 62103065 A KR 9403755 B1 MX 9202765 A1	04-02-1987 01-03-1988 13-06-1991 30-07-1990 13-05-1987 30-04-1994 30-06-1992
DE 19756261 A	01-07-1999	DE 19756261 A1 AU 2274099 A WO 9931064 A1 EP 1042291 A1 JP 2002508357 T ZA 9811240 A	01-07-1999 05-07-1999 24-06-1999 11-10-2000 19-03-2002 08-06-1999
WO 9802170 A	22-01-1998	CA 2260771 A1 EP 0979088 A1 WO 9802170 A1	22-01-1998 16-02-2000 22-01-1998